Message from Joe Biden and government commitment to ending cancer

During his final State of the Union, the President put me in charge of a new national commitment to ending cancer as we know it.

We’re calling it a “Moonshot,” and that’s because I believe that this effort, like President Kennedy’s call to land on the moon 55 years ago, is truly a call to humankind — to be bold and do big things.

And right now, I’m about to walk into the very first meeting of the Cancer Moonshot Task Force the President just created, and tasked me with chairing.

Here’s what it all means.

Every single federal agency with a part to play in this mission — from the National Institutes of Health and Food and Drug Administration to the Department of Veterans Affairs and Department of Energy and its national energy labs — will be in the same room together to make sure we’re working from the same playbook.

We’ll make sure we’re making the most of investments, of our research and data, our supercomputing capabilities, our targeted incentives, private-sector efforts, and patient-engagement initiatives.

In fact, just today we announced a new 1 billion dollar jumpstart to make sure some of the best work going on has the funding that it needs.

Because ultimately, as the federal government, our job is to break down silos and bring people together who are doing the most cutting-edge work. Our job is to clear out the bureaucratic hurdles — and let science happen.

And we’re going to continue to call on families, researchers, and physicians all across the country to join this effort and rise to the challenge.

I’ve been in touch with hundreds of the world’s top cancer physicians, researchers, and philanthropists.

And I’ve been in touch with Americans around the country who know the realities of this disease firsthand, people who have lived through it and people who have lost their loved ones they hold most dearly.

If you’ve got a story to tell about how this disease has touched your life, I want to hear from you.

And following the meeting, at around 3:30 p.m. Eastern, Dr. Francis Collins, Director of the National Institutes of Health, and Dr. Douglas Lowy, Chief of the National Cancer Institute’s Laboratory of Cellular Oncology, will be taking your questions on Twitter. You can ask them using #CancerMoonshot.

As the President said in the State of the Union, we can do this for the loved ones we’ve lost — and the families we can still save.

I couldn’t agree more. If there is one word that defines us as Americans, it’s “possibility.” And I believe this is possible.

I know that we can do this.

I’ll be in touch along the way with ways you can help — believe it.

Thank you,

Joe

Cambridge Biomedical Names Brad Yount as President and Chief Operating Officer

Cambridge Biomedical announced that Board Member Brad Yount has been appointed President and Chief Operating Officer reporting to Barbara Osband, Chief Executive Officer.

Brad Yount President & COO

“Cambridge Biomedical’s strength in bioanalytical assays and diagnostic testing is well known in the industry”

Boston, MA (PRWEB) June 15, 2015

Cambridge Biomedical announced that Board Member Brad Yount has been appointed President and Chief Operating Officer reporting to Barbara Osband, Chief Executive Officer.

“Brad is a seasoned leader with extensive experience in developing companies and driving them to the next level. Brad has provided his knowledge and expertise to Cambridge Biomedical as a board member since January, 2010. I have tremendous confidence that his inside knowledge of our operations combined with his management experience will further grow our company,” said Barbara Osband, Chief Executive Officer.

Yount assumed responsibility in May for all operational areas in Cambridge Biomedical and is focused on improving operational efficiencies within the company as it positions itself for continuing double-digit growth.

“Cambridge Biomedical’s strength in bioanalytical assays and diagnostic testing is well known in the industry,” Yount, President and COO, commented, “and I am greatly energized to help lead this company with its team of highly experienced staff through its next phase of growth tied to operational excellence.”

Prior to this appointment, Yount was responsible for the operations of several different companies in market research, architecture design and products, and speciality materials. Mr. Yount received a BS in Mechanical Engineering from Virginia Tech and a MBA from Northeastern University.

About Cambridge Biomedical

Cambridge Biomedical, based in Boston, Massachusetts, supports sponsors by developing customized assays for small and large molecules, biomarkers, and other critical analytes, along with validation and sample testing in our CLIA certified and CAP accredited, GLP/GCLP compliant facilities.

The Company has extensive expertise in technology transfer, assay development, optimization and validation. It also offers specific services in analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis, and testing services in support of clinical trial and drug or device development.

Our personalized project methodology, along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensures we meet our client’s product development timelines.